2022
Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action
Dousa K, Nguyen D, Kurz S, Taracila M, Bethel C, Schinabeck W, Kreiswirth B, Brown S, Boom W, Hotchkiss R, Remy K, Jacono F, Daley C, Holland S, Miller A, Bonomo R. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action. MBio 2022, 13: e03529-21. PMID: 35073757, PMCID: PMC8787486, DOI: 10.1128/mbio.03529-21.Peer-Reviewed Original ResearchConceptsD-carboxypeptidaseB-lactamB-lactamaseDisrupt cell wall synthesisStable acyl-enzyme complexesCell wall synthesisAcyl-enzyme complexMichaelis-Menten complexB-lactamase inhibitorsWall synthesisPeptidoglycan synthesisStructural lung diseaseTriple drug combinationIsolates to amoxicillinCell-based assaysMycobacterium abscessusMIC rangeImipenemMichaelis constantAcylation rateInhibitor combinationsDurlobactamMultidrug resistanceTherapeutic regimensCystic fibrosis
2021
“One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes
Nguyen D, Dousa K, Kurz S, Brown S, Drusano G, Holland S, Kreiswirth B, Boom W, Daley C, Bonomo R. “One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases 2021, 73: 1532-1536. PMID: 34113990, PMCID: PMC8677594, DOI: 10.1093/cid/ciab535.Peer-Reviewed Original ResearchConceptsPeptidoglycan synthesis enzymesMinimum inhibitory concentration of clinical isolatesB-lactamCombination of imipenemSynthesis enzymesSynergistic in vitroClinical isolatesMinimum inhibitory concentrationMycobacterium abscessusClinical trialsMycobacterial infectionAbscessusEnzymeCeftarolineImipenem
2020
1572. Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium abscessus
Dousa K, Nguyen D, Kurz S, Taracila M, Bethel C, Bonomo R. 1572. Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium abscessus. Open Forum Infectious Diseases 2020, 7: s785-s785. PMCID: PMC7778327, DOI: 10.1093/ofid/ofaa439.1752.Peer-Reviewed Original ResearchQualified Infectious Disease ProductFood and Drug AdministrationMab infectionClinical isolatesColony-forming unitsCell wall synthesis proteinsMycobacterium abscessusB-lactamOral step-down therapyNontuberculous mycobacteriaStep-down therapyUS Food and Drug AdministrationB-lactam antibioticsVisible bacterial growthMiddlebrook 7H9 brothCharacterized isolatesMIC distributionSynthesis proteinsClinical strainsOral formulationMAB isolatesClinical trialsActivity in vitroDrug AdministrationBacterial growth
2018
786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection?
Dousa K, Kreiswirth B, Kurz S, Bonomo R. 786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection? Open Forum Infectious Diseases 2018, 5: s281-s281. PMCID: PMC6254396, DOI: 10.1093/ofid/ofy210.793.Peer-Reviewed Original ResearchB-lactamB-lactamase inhibitorsMycobacterium abscessus infectionB-lactam antibioticsBenefits of combinationB-lactamaseCeftarolineHydrolyzed penicillinsMycobacterium abscessusAvibactamDiazabicyclooctane inhibitorBlaMabMycobacterial infectionMicrodilution methodClinical modelDiazabicyclooctaneInhibitorsInfectionMICInhibited growthNovel combinationCarbapenemsPotential combinationRelebactamMIC90
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply